Published in Antimicrob Agents Chemother on April 12, 2010
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis (2014) 2.65
Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae. Antimicrob Agents Chemother (2015) 0.86
DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis (2012) 0.85
Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy. ISRN Pharmacol (2012) 0.80
Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. Expert Rev Clin Pharmacol (2013) 0.77
Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. Antimicrob Agents Chemother (2015) 0.76
Pharmacodynamic variability beyond that explained by MICs. Antimicrob Agents Chemother (2013) 0.75
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther (2016) 0.75
Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers. Antimicrob Agents Chemother (2011) 0.75
Modeling approach to characterize intraocular doripenem pharmacokinetics after intravenous administration to rabbits, with tentative extrapolation to humans. Antimicrob Agents Chemother (2012) 0.75
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 16.20
The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest (2000) 9.51
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis (2005) 8.77
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol (2004) 5.19
The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother (2003) 3.61
Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis (2007) 3.30
Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis (2000) 3.01
Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med (1996) 2.72
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med (2008) 2.37
Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis (2005) 1.86
Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad Med (2008) 1.55
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother (2005) 1.50
Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother (2005) 1.41
Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis (2009) 1.32
Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob (2008) 1.29
Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect (2007) 1.27
Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol (2006) 1.21
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin (2008) 1.18
Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care (2008) 1.17
Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother (2006) 1.09
Continuous infusion of beta-lactams. Curr Opin Crit Care (2007) 1.08
Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit Care (2008) 1.04
Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother (2009) 1.02
Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis (2008) 1.01
Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother (2010) 1.01
The application of population pharmacokinetic modeling to individualized antibiotic therapy. Int J Antimicrob Agents (2002) 0.95
Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy (2007) 0.93
In vitro activity of doripenem. Clin Infect Dis (2009) 0.92
Overview of seizure-inducing potential of doripenem. Drug Saf (2009) 0.87
Safety of intravenous infusion of doripenem. Clin Infect Dis (2009) 0.86
Optimizing use of beta-lactam antibiotics in the critically ill. Semin Respir Crit Care Med (2007) 0.80
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2005) 4.22
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother (2005) 2.72
In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother (2003) 2.60
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med (2008) 2.37
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother (2004) 2.17
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother (2004) 2.01
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother (2007) 1.93
Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother (2002) 1.70
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Agents Chemother (2009) 1.37
The dose response and effects of dexamethasone on bupivacaine microcapsules for intercostal blockade (T9 to T11) in healthy volunteers. Anesth Analg (2003) 1.28
Characterization and prevalence of MefA, MefE, and the associated msr(D) gene in Streptococcus pneumoniae clinical isolates. J Clin Microbiol (2004) 1.27
A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care (2012) 1.18
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin (2008) 1.18
Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2005) 1.17
Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother (2005) 1.12
Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother (2009) 1.09
Exploring the positional attachment of glycopeptide/beta-lactam heterodimers. J Antibiot (Tokyo) (2008) 1.01
Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J (2012) 0.96
In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother (2005) 0.92
Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother (2008) 0.90
Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age. Epilepsia (2010) 0.89
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. Antimicrob Agents Chemother (2010) 0.88
Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother (2009) 0.88
Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models. J Pharmacokinet Pharmacodyn (2011) 0.84
A multivalent approach to drug discovery for novel antibiotics. J Antibiot (Tokyo) (2008) 0.84
The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class. Bioorg Med Chem Lett (2002) 0.84
Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother (2009) 0.83
A model to evaluate the pharmacokinetic and pharmacodynamic variables of extended-release products using in vivo tissue microdialysis in humans: bupivacaine-loaded microcapsules. Anesth Analg (2003) 0.83
Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clin Pharmacokinet (2010) 0.82
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials. Int J Antimicrob Agents (2013) 0.81
Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries. J Pharmacokinet Pharmacodyn (2013) 0.80
Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy. ISRN Pharmacol (2012) 0.80
Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet (2014) 0.79
In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method. Diagn Microbiol Infect Dis (2012) 0.78
Modeling of bounded outcome scores with data on the boundaries: application to disability assessment for dementia scores in Alzheimer's disease. AAPS J (2014) 0.77
Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials. Curr Med Res Opin (2009) 0.77
Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. Clin Ther (2002) 0.77
Analysis of dose-response in flexible dose titration clinical studies. Pharm Stat (2012) 0.77
Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR. Pharm Res (2012) 0.77
On average: data exploration based on means can be misleading. AAPS J (2011) 0.75
696: FREQUENCY OF OCCURRENCE AND ANTIMICROBIAL SUSCEPTIBILITY OF BACTERIA IN ICU PATIENTS WITH PNEUMONIA. Crit Care Med (2016) 0.75
650: CEFTAZIDIME/AVIBACTAM ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA FROM ICU AND NON-ICU PATIENTS. Crit Care Med (2016) 0.75